Do analysts recommend SNOA or OPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer SNOA or TVRD?

Tvardi Therapeutics has a consensus price target of $18.00, indicating a potential upside of 922.73%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Do analysts rate TXMD or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate COCP or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BFRI or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Sonoma Pharmaceuticals (SNOA) Competitors

$1.28 -0.01 (-0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$1.28 0.00 (0.00%)

As of 04:15 PM Eastern

Compare

SNOA vs. OPTH, TVRD, TXMD, COCP, and BFRI

Should you buy Sonoma Pharmaceuticals stock or one of its competitors? Sonoma Pharmaceuticals's main competitors and comparable companies include Optimi Health (OPTH), Tvardi Therapeutics (TVRD), TherapeuticsMD (TXMD), Cocrystal Pharma (COCP), and Biofrontera (BFRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sonoma Pharmaceuticals compare to Optimi Health?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Optimi Health has lower revenue, but higher earnings than Sonoma Pharmaceuticals. Optimi Health is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.31	-$3.17M	-$1.22	N/A
Optimi Health	$175.67K	165.26	-$1.12M	-$0.76	N/A

In the previous week, Optimi Health had 7 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 8 mentions for Optimi Health and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 1.89 beat Optimi Health's score of 0.35 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Very Positive
Optimi Health	Neutral

Optimi Health has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Optimi Health's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%
Optimi Health	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Optimi Health beats Sonoma Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Tvardi Therapeutics?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Tvardi Therapeutics had 4 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 5 mentions for Tvardi Therapeutics and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 1.89 beat Tvardi Therapeutics' score of 0.97 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Very Positive
Tvardi Therapeutics	Positive

Tvardi Therapeutics has a consensus price target of $18.00, indicating a potential upside of 922.73%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Tvardi Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%
Tvardi Therapeutics	N/A	-145.40%	-91.11%

Sonoma Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Sonoma Pharmaceuticals has higher revenue and earnings than Tvardi Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.31	-$3.17M	-$1.22	N/A
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$2.79	N/A

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Tvardi Therapeutics beats Sonoma Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

In the previous week, TherapeuticsMD and TherapeuticsMD both had 1 articles in the media. TherapeuticsMD's average media sentiment score of 1.89 equaled Sonoma Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Sonoma Pharmaceuticals	Very Positive

TherapeuticsMD has higher earnings, but lower revenue than Sonoma Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.28	-$570K	$0.02	108.00
Sonoma Pharmaceuticals	$19.53M	0.31	-$3.17M	-$1.22	N/A

TherapeuticsMD has a net margin of -6.64% compared to Sonoma Pharmaceuticals' net margin of -10.33%. TherapeuticsMD's return on equity of -1.09% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

Summary

TherapeuticsMD beats Sonoma Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Cocrystal Pharma had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 2 mentions for Cocrystal Pharma and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 1.89 beat Cocrystal Pharma's score of 0.94 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Positive
Sonoma Pharmaceuticals	Very Positive

Cocrystal Pharma has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Sonoma Pharmaceuticals has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	$330K	66.54	-$8.83M	-$0.76	N/A
Sonoma Pharmaceuticals	$19.53M	0.31	-$3.17M	-$1.22	N/A

Cocrystal Pharma has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cocrystal Pharma beats Sonoma Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Biofrontera has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

In the previous week, Biofrontera had 5 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 6 mentions for Biofrontera and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 1.89 beat Biofrontera's score of 0.70 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Biofrontera	Positive
Sonoma Pharmaceuticals	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sonoma Pharmaceuticals has a net margin of -10.33% compared to Biofrontera's net margin of -13.78%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

Sonoma Pharmaceuticals has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$46.18M	0.38	-$10.54M	-$0.45	N/A
Sonoma Pharmaceuticals	$19.53M	0.31	-$3.17M	-$1.22	N/A

Summary

Biofrontera beats Sonoma Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Sonoma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNOA vs. The Competition

Export

Metric	Sonoma Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.13M	$12.44B	$7.16B	$14.34B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-1.05	792.10	273.41	25.32
Price / Sales	0.31	763.25	674.51	98.42
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	1.97	10.40	10.38	6.20
Net Income	-$3.17M	$2.83B	$3.49B	$358.18M
7 Day Performance	-3.76%	-3.28%	-2.17%	-1.58%
1 Month Performance	-1.54%	0.80%	-0.37%	-3.60%
1 Year Performance	-71.11%	3.62%	19.18%	5.95%

Sonoma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNOA Sonoma Pharmaceuticals	0.8478 of 5 stars	$1.28 -0.8%	N/A	-71.1%	$6.13M	$19.53M	N/A	180	Positive News
OPTH Optimi Health	1.2029 of 5 stars	$4.35 -10.1%	N/A	N/A	$24.91M	$175.67K	N/A	N/A	Short Interest Decrease High Trading Volume
TVRD Tvardi Therapeutics	3.694 of 5 stars	$1.85 -4.6%	$18.00 +873.0%	-94.6%	$24.68M	N/A	N/A	80	News Coverage Analyst Upgrade
TXMD TherapeuticsMD	1.5198 of 5 stars	$2.12 -0.9%	N/A	+94.6%	$24.53M	$3.02M	106.00	420	Positive News
COCP Cocrystal Pharma	0.8497 of 5 stars	$1.24 +5.1%	N/A	-25.9%	$23.89M	$330K	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNOA) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. OPTH, TVRD, TXMD, COCP, and BFRI

How does Sonoma Pharmaceuticals compare to Optimi Health?

Summary

How does Sonoma Pharmaceuticals compare to Tvardi Therapeutics?

Summary

How does Sonoma Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Sonoma Pharmaceuticals compare to Cocrystal Pharma?

Summary

How does Sonoma Pharmaceuticals compare to Biofrontera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. OPTH, TVRD, TXMD, COCP, and BFRI

How does Sonoma Pharmaceuticals compare to Optimi Health?

Which has stronger valuation and earnings, SNOA or OPTH?

Does the media favor SNOA or OPTH?

Is SNOA or OPTH more profitable?

Do analysts recommend SNOA or OPTH?

Do institutionals and insiders hold more shares of SNOA or OPTH?

Summary

How does Sonoma Pharmaceuticals compare to Tvardi Therapeutics?

Does the media favor SNOA or TVRD?

Do analysts prefer SNOA or TVRD?

Is SNOA or TVRD more profitable?

Which has more volatility & risk, SNOA or TVRD?

Which has stronger earnings & valuation, SNOA or TVRD?

Do institutionals & insiders believe in SNOA or TVRD?

Summary

How does Sonoma Pharmaceuticals compare to TherapeuticsMD?

Do institutionals and insiders hold more shares of TXMD or SNOA?

Do analysts rate TXMD or SNOA?

Which has more volatility and risk, TXMD or SNOA?

Does the media refer more to TXMD or SNOA?

Which has stronger valuation & earnings, TXMD or SNOA?

Is TXMD or SNOA more profitable?

Summary

How does Sonoma Pharmaceuticals compare to Cocrystal Pharma?

Do insiders & institutionals hold more shares of COCP or SNOA?

Does the media prefer COCP or SNOA?

Which has more risk and volatility, COCP or SNOA?

Which has higher valuation and earnings, COCP or SNOA?

Is COCP or SNOA more profitable?

Do analysts rate COCP or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to Biofrontera?

Do insiders & institutionals hold more shares of BFRI or SNOA?

Which has more volatility and risk, BFRI or SNOA?

Does the media prefer BFRI or SNOA?

Do analysts prefer BFRI or SNOA?

Is BFRI or SNOA more profitable?

Which has preferable valuation and earnings, BFRI or SNOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools